Open an account

Actuate Therapeutics

ACTU · NASDAQ

$0.6161+$0.0171 (+2.85%)TodayMarket closed ·
Prev close $0.599

About ACTU

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. The company is headquartered in Fort Worth, Texas and currently employs 12 full-time employees. The company went IPO on 2024-08-13. The firm is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The firm is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Employees
12
Headquarters
Fort Worth, Texas
Listed
Aug 13, 2024
Sector
Health Care
Industry
Biotechnology
Website
actuatetherapeutics.com

ACTU key statistics

Market cap
14.80M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
402.49K
Volume
166.70K
Open price
$0.5926
High today
$0.6618
Low today
$0.5462
52 Week high
$7.90
52 Week low
$0.41

Actuate Therapeutics (ACTU) at a glance

Actuate Therapeutics (ACTU) last traded at $0.6161, with a market cap of 14.80M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.5462 and $0.6618. The current price is 12.8% above the day's low and 6.9% below its high.

Volume so far is 166.70K shares, below the average of 402.49K shares a day.

Over the past year Actuate Therapeutics has ranged from $0.41 to $7.90, and now sits 3% of the way up that range.

Actuate Therapeutics met or beat analyst EPS estimates in 3 of the last 7 quarters. In Q2 FY26 it reported -$0.20 per share against an estimate of -$0.1904.

The average analyst price target is $11.90, 1831.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $11.90
Low
$8.08
Now
$0.6161
High
$15.75

ACTU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 7 quarters, by 14.4% on average.

  1. Q4 FY24: reported -$0.33 per share against an estimate of -$0.2958
  2. Q1 FY25: reported -$0.32 per share against an estimate of -$0.3094
  3. Q2 FY25: reported -$0.31 per share against an estimate of -$0.3213
  4. Q3 FY25: reported -$0.25 per share against an estimate of -$0.2831
  5. Q4 FY25: reported -$0.18 per share against an estimate of -$0.2499
  6. Q1 FY26: reported -$0.24 per share against an estimate of -$0.221
  7. Q2 FY26: reported -$0.20 per share against an estimate of -$0.1904

ACTU news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Mohd Haider

    Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseBusiness Wire

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Similar companies

Companies in the same industry as Actuate Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.